文献速递主动脉疾病

应用EDUCATe计划在VISION网络中分析血管腔内主动脉修复术后长期结局

Using the Evaluating Devices Using Claims and RegisTry Data (EDUCATe) Plan within the Vascular Implant Surveillance and Interventional Outcomes Network (VISION) to Analyze the Long-Term Outcomes following Endovascular Aortic Aneurysm Repair.
PubMed 文献 · Ann Vasc Surg · 2022-11-19

本研究将2项行业赞助的EVAR器械IDE临床试验患者与VISION注册数据库进行患者层面匹配,比较两种来源的长期器械结局。159例临床试验患者中134例符合匹配条件,115例(85.5%)成功匹配;匹配队列1年、3年、5年生存率分别为94.8%、82.6%、68.1%,免于再干预率分别为90%、82.4%、78.1%。临床试验数据与VISION数据的生存估计几乎一致(log-rank P=0.89),免于再干预率相似(log-rank P=0.13)。

要点

  • 临床试验EVAR患者可成功匹配至基于理赔的注册数据以改善长期器械监测
  • 匹配队列5年生存率为68.1%,5年免于再干预率为78.1%
  • 临床试验与VISION数据的生存估计几乎一致(log-rank P=0.89),免于再干预率相似(log-rank P=0.13)

核心结论

  • 接受EVAR的临床试验患者可成功匹配至基于理赔的注册数据,从而改善长期器械监测与结局报告;基于理赔的结果在5年内与IDE试验结果吻合良好,支持基于理赔数据用于更长期监测的准确性;将临床试验与基于理赔的注册数据关联可实现对器械的稳健监测。

研究设计与样本

  • 本研究将2项行业赞助的EVAR器械IDE临床试验的患者层面数据(由单一行业合作方提供)在患者层面匹配至VISION注册数据,该注册属于血管外科学会患者安全组织的一部分;159例临床试验患者中134例符合基于理赔的匹配条件,115例(85.5%)成功匹配至VISION注册数据;主要分析结局为生存率与免于动脉瘤相关再干预率。

主要发现

  • 匹配队列的Kaplan-Meier估计生存率1年为94.8%、3年为82.6%、5年为68.1%。
  • 匹配队列估计免于再干预率1年为90%、3年为82.4%、5年为78.1%。
  • 生存估计在临床试验数据与VISION数据之间几乎一致(log-rank P=0.89)。
  • 免于再干预率在两组间相似:IDE试验报告的1年与5年免于再干预率分别为87.3%与73.3%,VISION分别为92.6%与83%(log-rank P=0.13)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Implanted devices undergo clinical trials to assess their safety and effectiveness. However, pivotal device trials are limited in their follow-up while postmarket surveillance may incompletely capture late failure. Linking clinical trials to Medicare claims can address these limitations. This study matched patients from investigational device exemption (IDE) clinical trials for endovascular aortic aneurysm repair (EVAR) to Medicare claims-based registry data to compare long-term device outcomes between the 2 sources. METHODS: Patient-level data from 2 industry-sponsored IDE trials of EVAR devices was provided by a single industry partner. Trial data were matched at the patient level to data from the Vascular Implant Surveillance and Interventional Outcomes Network (VISION), a registry that is a part of the Society for Vascular Surgery Patient Safety Organization. The primary outcomes analyzed were survival and freedom from aneurysm-related reintervention. RESULTS: Of 159 clinical trial patients, 134 were eligible for claims-based matching and 115 (85.5%) were successfully matched to VISION registry data. For the matched cohort, the Kaplan-Meier estimated survival was 94.8% at 1 year, 82.6% at 3 years, and 68.1% at 5 years. Estimates for freedom from reintervention were 90% at 1 year, 82.4% at 3 years, and 78.1% at 5 years. The estimates for survival were nearly identical between the clinical trial data and that found in the VISION data (log-rank P = 0.89). Freedom from reintervention was similar between the groups, with IDE trial reported freedom from reintervention of 87.3% and 73.3%, compared to VISION of 92.6% and 83% at 1 and 5 years, respectively (log-rank P = 0.13). CONCLUSIONS: Clinical trial patients who undergo EVAR can be successfully matched to claims-based registry data to improve long-term device surveillance and outcomes reporting. Claims-based results agreed well with IDE trial results for patients through 5 years, supporting the accuracy of claims-based data for longer-term surveillance. Linking clinical trial and claims-based registry data can lead to robust device monitoring.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Suckow BD, Mao J, Williams S, et al. Using the Evaluating Devices Using Claims and RegisTry Data (EDUCATe) Plan within the Vascular Implant Surveillance and Interventional Outcomes Network (VISION) to Analyze the Long-Term Outcomes following Endovascular Aortic Aneurysm Repair. Ann Vasc Surg. 2022. PMID: 36410641. doi:10.1016/j.avsg.2022.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。